title: Circulating stem cell collection in lymphoma and myeloma after mobilization with cyclophosphamide and granulocyte colony-stimulating factor for autologous transplantation.
abstract: We report the results of 72 leukapheresis procedures performed for autologous peripheral blood stem cell collection in 18 patients with lymphoma and myeloma, after combined mobilization with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF). The numbers of mononuclear cells (MNCs), CD34+ cells and granulocyte-macrophage colony-forming units (CFU-GM) either in the peripheral circulation (preleukapheresis sample) or in the product obtained from leukapheresis (leukapheresis sample) were evaluated. A highly superior proportion of CD34+ cells (14-fold) and CFU-GM (5-fold) resulted from the mobilization therapy. CFU-GM and CD34+ cells were highly enriched with respect to all MNCs (relative recoveries: 2.13, range 0.3-41, and 1.08, range 0.2-8.5, respectively) due to an additional mobilization effect by the leukapheresis procedure. Also, a relatively strong linear correlation between the three different parameters was found in the leukapheresis product (CD34+:CFU-GM, r = 0.81; MNCs:CD34, r = 0.69; MNCs:CFU-GM, r = 0.75; CFU-GM:CD34+, and MNCs, r = 0.85). Our data suggest that the number of MNCs and CD34+ cells obtained after combined mobilization with cyclophosphamide and G-CSF can be used as predictor of the number of granulomonocytic progenitors.
authors.affiliation: Department of Haematology, Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Cancelas
authors.forename: M
authors.initials: M
authors.lastname: Hernández-Jodra
authors.forename: C
authors.initials: C
authors.lastname: Zamora
authors.forename: J
authors.initials: J
authors.lastname: Perez-Oteyza
authors.forename: J A
authors.initials: JA
authors.lastname: Brieva
authors.forename: E
authors.initials: E
authors.lastname: Roldan
authors.forename: G
authors.initials: G
authors.lastname: Navas
authors.forename: J
authors.initials: J
authors.lastname: Garcia-Laraña
authors.forename: J
authors.initials: J
authors.lastname: Lopez
authors.forename: J
authors.initials: J
authors.lastname: Odriozola
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34; D001773:Blood Cells; D002469:Cell Separation / Q000379:methods*; D003520:Cyclophosphamide / Q000494:pharmacology*; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006689:Hodgkin Disease / Q000097:blood / Q000628:therapy; D006801:Humans; D007937:Leukapheresis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008223:Lymphoma / Q000097:blood* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000628:therapy; D009101:Multiple Myeloma / Q000097:blood* / Q000628:therapy
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide